The use of COA in patient-centered drug development: part 1 2w5a

From introduction to interpretation, Dan O’Connor and Chad Gwaltney as they explore how best to meet the expectations of regulatory authorities. Including: demystifying COA guidance documents and discussing how they became an integral part of the regulatory landscape. 3b2e40